Ignite Creation Date:
2024-05-06 @ 9:27 AM
Last Modification Date:
2024-10-26 @ 12:14 PM
Study NCT ID:
NCT02989714
Status:
COMPLETED
Last Update Posted:
2021-07-13
First Post:
2016-12-08
Brief Title:
Phase IbII Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor Nivolumab In Metastatic Clear Cell Renal Cell Cancer
Sponsor:
University of Michigan Rogel Cancer Center
Organization:
University of Michigan Rogel Cancer Center
Organization Data
Organization:
University of Michigan Rogel Cancer Center
Class:
OTHER
Study ID:
UMCC 2016103
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
University of Michigan Rogel Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None